Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study.

Karlowsky JA, Lagacé-Wiens PR, Simner PJ, DeCorby MR, Adam HJ, Walkty A, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2011 Jul;55(7):3169-75. doi: 10.1128/AAC.00066-11. Epub 2011 May 2.

2.

In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study).

Walkty A, DeCorby M, Lagacé-Wiens PR, Karlowsky JA, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2011 Jun;55(6):2992-4. doi: 10.1128/AAC.01696-10. Epub 2011 Mar 21.

3.

In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.

Karlowsky JA, Adam HJ, Decorby MR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2011 Jun;55(6):2837-46. doi: 10.1128/AAC.01787-10. Epub 2011 Mar 14.

4.

Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.

Lagacé-Wiens PR, Tailor F, Simner P, DeCorby M, Karlowsky JA, Walkty A, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2011 May;55(5):2434-7. doi: 10.1128/AAC.01722-10. Epub 2011 Feb 28.

5.

Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada--results of the CANWARD 2007-2009 study.

Lagacé-Wiens PR, Simner PJ, Forward KR, Tailor F, Adam HJ, Decorby M, Karlowsky J, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):314-9. doi: 10.1016/j.diagmicrobio.2010.10.027.

PMID:
21353959
6.

Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 study.

Adam HJ, DeCorby M, Rennie R, Karlowsky JA, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):307-13. doi: 10.1016/j.diagmicrobio.2010.10.026.

PMID:
21353958
7.

Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study.

Zhanel GG, Adam HJ, Low DE, Blondeau J, Decorby M, Karlowsky JA, Weshnoweski B, Vashisht R, Wierzbowski A, Hoban DJ; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):291-306. doi: 10.1016/j.diagmicrobio.2010.10.025.

PMID:
21353957
8.

Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008).

Zhanel GG, DeCorby M, Adam H, Mulvey MR, McCracken M, Lagacé-Wiens P, Nichol KA, Wierzbowski A, Baudry PJ, Tailor F, Karlowsky JA, Walkty A, Schweizer F, Johnson J; Canadian Antimicrobial Resistance Alliance, Hoban DJ.

Antimicrob Agents Chemother. 2010 Nov;54(11):4684-93. doi: 10.1128/AAC.00469-10. Epub 2010 Aug 30.

9.

In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008.

Walkty A, DeCorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2009 Nov;53(11):4924-6. doi: 10.1128/AAC.00786-09. Epub 2009 Aug 24.

10.

Identification of multidrug- and carbapenem-resistant Acinetobacter baumannii in Canada: results from CANWARD 2007.

McCracken M, DeCorby M, Fuller J, Loo V, Hoban DJ, Zhanel GG, Mulvey MR.

J Antimicrob Chemother. 2009 Sep;64(3):552-5. doi: 10.1093/jac/dkp225. Epub 2009 Jul 3.

PMID:
19578083
11.

Differences in antimicrobial susceptibility in Escherichia coli from Canadian intensive care units based on regional and demographic variables.

Lagacé-Wiens PR, Decorby MR, Baudry PJ, Hoban DJ, Karlowsky JA, Zhanel GG; CAN-ICU study group.

Can J Infect Dis Med Microbiol. 2008 Jul;19(4):282-6.

13.

Mechanisms of resistance and mobility among multidrug-resistant CTX-M-producing Escherichia coli from Canadian intensive care units: the 1st report of QepA in North America.

Baudry PJ, Nichol K, DeCorby M, Lagacé-Wiens P, Olivier E, Boyd D, Mulvey MR, Hoban DJ, Zhanel GG.

Diagn Microbiol Infect Dis. 2009 Mar;63(3):319-26. doi: 10.1016/j.diagmicrobio.2008.12.001.

PMID:
19216943
14.

ESBL genotypes in fluoroquinolone-resistant and fluoroquinolone-susceptible ESBL-producing Escherichia coli urinary isolates in Manitoba.

Lagacé-Wiens PR, Nichol KA, Nicolle LE, Decorby MR, McCracken M, Alfa MJ, Mulvey MR, Zhanel GG.

Can J Infect Dis Med Microbiol. 2007 Mar;18(2):133-7.

15.

Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.

Zhanel GG, DeCorby M, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, Lagacé-Wiens P, Walkty A, Mulvey MR, Hoban DJ; Canadian Antimicrobial Resistance Alliance.

Diagn Microbiol Infect Dis. 2008 Sep;62(1):67-80. doi: 10.1016/j.diagmicrobio.2008.04.012. Epub 2008 May 29.

PMID:
18513913
16.

In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study.

Walkty A, Decorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2008 Jul;62(1):206-8. doi: 10.1093/jac/dkn140. Epub 2008 Apr 1. No abstract available.

PMID:
18385143
17.

Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian intensive care units as part of the Canadian National Intensive Care Unit study.

Walkty A, Decorby M, Nichol K, Mulvey MR, Hoban D, Zhanel G; Canadian Antimicrobial Resistance Alliance.

Diagn Microbiol Infect Dis. 2008 Jun;61(2):217-21. doi: 10.1016/j.diagmicrobio.2008.01.009. Epub 2008 Mar 4.

PMID:
18304774
18.

Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.

Baudry PJ, Nichol K, DeCorby M, Mataseje L, Mulvey MR, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2008 May;52(5):1846-9. doi: 10.1128/AAC.01176-07. Epub 2008 Feb 25.

19.

Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.

Zhanel GG, DeCorby M, Laing N, Weshnoweski B, Vashisht R, Tailor F, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, Lagacé-Wiens P, Walkty A, McCracken M, Mulvey MR, Johnson J; Canadian Antimicrobial Resistance Alliance (CARA), Hoban DJ.

Antimicrob Agents Chemother. 2008 Apr;52(4):1430-7. doi: 10.1128/AAC.01538-07. Epub 2008 Feb 19.

20.

Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.

Zhanel GG, Trapp S, Gin AS, DeCorby M, Lagacé-Wiens PR, Rubinstein E, Hoban DJ, Karlowsky JA.

Expert Rev Anti Infect Ther. 2008 Feb;6(1):67-81. doi: 10.1586/14787210.6.1.67. Review.

PMID:
18251665
22.

Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA).

Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Weshnoweski B, Johnson J, Noreddin A, Low DE, Karlowsky JA; NAUTICA Group, Hoban DJ.

Int J Antimicrob Agents. 2006 Jun;27(6):468-75. Epub 2006 May 18.

PMID:
16713191
23.

Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates.

Adam HJ, Schurek KN, Decorby MR, Weshnoweski B, Vashisht R, Karlowsky K, Hoban DJ, Zhanel GG.

J Antimicrob Chemother. 2006 Jul;58(1):202-4. Epub 2006 Apr 24.

PMID:
16636082
24.

The use of macrolides in treatment of upper respiratory tract infections.

Wierzbowski AK, Hoban DJ, Hisanaga T, DeCorby M, Zhanel GG.

Curr Allergy Asthma Rep. 2006 Mar;6(2):171-81. Review.

PMID:
16566868
25.

Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.

Lagacé-Wiens PR, Nichol KA, Nicolle LE, DeCorby M, McCracken M, Mulvey MR, Zhanel GG.

J Antimicrob Chemother. 2006 Jun;57(6):1262-3. Epub 2006 Mar 24. No abstract available.

PMID:
16565157
26.

Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA).

Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Palatnik LP, Johnson J, Noreddin A, Harding GK, Nicolle LE, Hoban DJ; NAUTICA Group.

Int J Antimicrob Agents. 2005 Nov;26(5):380-8.

PMID:
16243229
27.

The Use of Macrolides in Treatment of Upper Respiratory Tract Infections.

Wierzbowski AK, Hoban DJ, Hisanaga T, Decorby M, Zhanel GG.

Curr Infect Dis Rep. 2005 May;7(3):175-184.

PMID:
15847719
28.

Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.

Zhanel GG, DeCorby M, Noreddin A, Mendoza C, Cumming A, Nichol K, Wierzbowski A, Hoban DJ.

J Antimicrob Chemother. 2003 Jul;52(1):83-8. Epub 2003 May 29.

PMID:
12775677

Supplemental Content

Loading ...
Support Center